Id: | acc2587 |
Group: | 1sens |
Protein: | IkappaBalpha |
Gene Symbol: | NFKBIA |
Protein Id: | P25963 |
Protein Name: | IKBA_HUMAN |
PTM: | phosphorylation |
Site: | Ser32 |
Site Sequence: | ERLLDDRHDSGLDSMKDEEYE |
Disease Category: | Cancer |
Disease: | Gastric Cancer |
Disease Subtype: | |
Disease Cellline: | BGC-823 |
Disease Info: | |
Drug: | Aloin |
Drug Info: | Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated?Wnt?and Bmp signaling pathways |
Relation: |
Aloin
➜
IkappaBalpha-Ser32
DOWN
➜
Gastric Cancer
Alleviate
|
Effect: | modulate |
Effect Info: | "inhibits the proliferation and migration of gastric cancer cells by downregulating the activation of NOX2-ROS-mediated Akt-mTOR, Stat3, and NF-kappaB signaling pathways." |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 32021099 |
Sentence Index: | 32021099_14 |
Sentence: | "N-acetylcysteine treatment of gastric cancer cells inhibited ROS production and Akt-mTOR, Stat3, and IkappaBalpha phosphorylation." |
Sequence & Structure:
MFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVPRGSEPWKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVITNQPEIAEALLGAGCDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATNYNGHTCLHLASIHGYLGIVELLVSLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNFKBIA-Ser32 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | |
HGSC | |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
S | 32 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
T | 32 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.